Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12613001211752
Ethics application status
Not yet submitted
Date submitted
2/11/2013
Date registered
5/11/2013
Date last updated
5/11/2013
Type of registration
Prospectively registered

Titles & IDs
Public title
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MRX-I Tablets in Healthy Adult Subjects (Part 2)
Scientific title
A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MRX-I Tablets in Healthy Adult Subjects (Part 2)
Secondary ID [1] 283501 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
This study is for healthy volunteers. The intended use of the investigational product is the treatment of serious gram-positive bacterial infections 290420 0
Condition category
Condition code
Infection 290812 290812 0 0
Studies of infection and infectious agents

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Part 2 has a double-blind, placebo-controlled, single cohort design. This part of the study will enroll 12 subjects in a single Dose Cohort (MRX-I Tablets 800 mg given once every 12 hours or placebo). Subjects will be screened and then randomized to study drug (active MRX-I or placebo) within this single Dose Cohort. Equal numbers of males and females will be randomized to either active or placebo study drug: 10 active MRX-I (5 M:5 F) and 2 placebo (1 M:1 F). Subjects will be treated for 14 days. Subjects will be confined in a Clinical Research Unit during the dosing periods and will be monitored to ensure compliance with dosing.
Intervention code [1] 288207 0
Treatment: Drugs
Comparator / control treatment
placebo: Tablet containing lactose and microcrystalline cellulose, magnesium stearate, and carnauba wax
Control group
Placebo

Outcomes
Primary outcome [1] 290806 0
Safety and tolerability as assessed through the determination and recording of the occurrence of AEs as well as by adverse changes in vital signs, ECG (e.g. QTc interval) parameters, and laboratory data.
Timepoint [1] 290806 0
From the time of signed consent through the end of study date which occurs on Day 23
Secondary outcome [1] 305337 0
To determine the pharmacokinetics of MRX-I as assessed through blood and urine collection during the study
Timepoint [1] 305337 0
Part 2: On Day 1, obtain blood for PK analyses immediately prior to administration of the first dose of study drug, and at 15 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12, 18, and 24 hours after the first administration study drug; obtain the 24-hour sample prior to the second administration of study drug on Day 2. On Day 5 and Day 6, obtain blood for PK analyses immediately prior to the first administration of study drug for that day. On Day 14, obtain blood for PK analyses immediately prior to the final administration of study drug, and at 15 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, and 48 hours after the final administration of study drug. On Day 1, obtain urine for PK analysis immediately prior to the first administration of study drug and at 0-2, 2-4, 4-8, 8-12, and 12-24 hours after the first administration of study drug; obtain the 12-24 hour sample prior to the second administration of study drug on Day 2. On Day 14, obtain urine for PK analysis immediately prior to the final administration of study drug and at 0-2, 2-4, 4-8, 8-12, 12-24, and 24-36 hours after the final administration of study drug.

Eligibility
Key inclusion criteria
This study will be conducted in normal, healthy, adult, male or female non-Chinese subjects aged between 18-50 years and with a BMI greater than or equal to 18 and less than or equal to 32. Eligible subjects will be in good health without signs or symptoms of current illness and with predose clinical and laboratory examinations without clinically significant findings.
Minimum age
18 Years
Maximum age
50 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
- History of any intolerance, hypersensitivity or allergic reaction to any oxazolidinone antibiotic
- History of bone marrow suppression or any type of anemia, leukopenia, thrombocytopenia, or pancytopenia
- History of peripheral or optic neuropathy
- History of hypoglycemia; low fasting glucose at screening (blood glucose level less than 50 mg/dL), even if normal upon repeat testing
- History of known or suspected serotonin syndrome, neuroleptic malignant syndrome, or carcinoid syndrome
- History of known or suspected lactic acidosis, unexplained acidosis, recurrent nausea and vomiting, or low bicarbonate levels associated with medication
- History of known or suspected Clostridium difficile-associated diarrhea
- Surgery or any acute illness within the past three months determined by the PI to be clinically relevant
- Females who are pregnant or nursing

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
9/12/2013
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
12
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 288202 0
Commercial sector/Industry
Name [1] 288202 0
MicuRx Pharmaceuticals
Country [1] 288202 0
United States of America
Primary sponsor type
Commercial sector/Industry
Name
CPR Pharma Services
Address
Suite C, 32 West Thebarton Road
Thebarton SA 5031
Country
Australia
Secondary sponsor category [1] 286928 0
None
Name [1] 286928 0
Address [1] 286928 0
Country [1] 286928 0

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 290114 0
BellBerry HREC
Ethics committee address [1] 290114 0
129 Glen Osmond Road
Eastwood South Australia 5063
Ethics committee country [1] 290114 0
Australia
Date submitted for ethics approval [1] 290114 0
31/10/2013
Approval date [1] 290114 0
Ethics approval number [1] 290114 0

Summary
Brief summary
The primary purpose of this study on healthy volunteers is to determine the safety and tolerability of MRX-I, an orally administered antibiotic. There will be three Parts to the study. Part 1 will assess the safety, tolerability and pharmacokinetics of single dose administrations of MRX-I compared with placebo. Part 2 will assess the safety, tolerability and pharmacokinetics of a 14 day administration of MRX-I compared with placebo. Part 3 will compare the safety and tolerability of a 28 day administration of MRX-I with linezolid an active comparator. (please refer to ACTRN12613001206718)
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 44034 0
Dr Jason Lickliter, MBBS PhD FRACP
Address 44034 0
Nucleus Network Limited Level
5 Burnet Institute AMREP Precinct
89 Commercial Road
Melbourne Victoria 3004
Country 44034 0
Australia
Phone 44034 0
+61 3 9076 8960
Fax 44034 0
Email 44034 0
[email protected]
Contact person for public queries
Name 44035 0
Jason Lickliter, MBBS PhD FRACP
Address 44035 0
Nucleus Network Limited Level
5 Burnet Institute AMREP Precinct
89 Commercial Road
Melbourne Victoria 3004
Country 44035 0
Australia
Phone 44035 0
+61 3 9076 8960
Fax 44035 0
Email 44035 0
[email protected]
Contact person for scientific queries
Name 44036 0
Paul Eckburg
Address 44036 0
MicuRx Pharmaceuticals, Inc.
3916 Trust Way Hayward, CA 94545
Country 44036 0
United States of America
Phone 44036 0
+1-650-888-3475
Fax 44036 0
Email 44036 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.